|Articles|July 11, 2012

Drug Cost Control in Oncology

Panel members are asked to discuss what drives the cost of drugs in cancer care. They also discuss the role companion diagnostics and personalized medicine play in oncology.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Immunotherapy Increases Melanoma Survival, Yet Toxicity Gaps Persist: Igor Puzanov, MD, MSCI, FACP

ByBrooke McCormick,Igor Puzanov, MD, MSCI, FACP ,Ella Hohmann, MS

June 7th 2026

Why CGM Access and Diabetes Amputations Are Part of the Same Systemic Problem: Alyson K. Myers, MD

ByGiuliana Grossi,Alyson K. Myers, MD

June 6th 2026

Culturally Tailored Diabetes Care Can Improve Outcomes and Reduce Costs: Alyson K. Myers, MD

ByGiuliana Grossi,Alyson K. Myers, MD

June 6th 2026

Health Equity & Access Weekly Roundup: June 5, 2026

ByGiuliana Grossi

June 5th 2026

FDA HQ | Image Credit: Tada Images - stock.adobe.com

5 Notable Oncology FDA Approvals Granted in May

ByBrooke McCormick

June 5th 2026

Drug Cost Control in Oncology

Related Content

Immunotherapy Increases Melanoma Survival, Yet Toxicity Gaps Persist: Igor Puzanov, MD, MSCI, FACP

Why CGM Access and Diabetes Amputations Are Part of the Same Systemic Problem: Alyson K. Myers, MD

Culturally Tailored Diabetes Care Can Improve Outcomes and Reduce Costs: Alyson K. Myers, MD

Health Equity & Access Weekly Roundup: June 5, 2026

5 Notable Oncology FDA Approvals Granted in May

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

AI Reshaping Diabetes Care From Nutrition to Clinical Decisions

Social Factors Shape Diabetes, Dementia Risk Across Populations

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD